Pharmaceutical Compositions for Specialized Environments

Publication ID: 24-11857625_0004_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Pharmaceutical Compositions for Specialized Environments,” Published Technical Disclosure No. 24-11857625_0004_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857625_0004_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,625.

Summary of the Inventive Concept

The inventive concept relates to pharmaceutical compositions adapted for specific, narrow markets or unique operational environments, such as disaster relief, high-security needs, extreme weather conditions, high-altitude use, and remote medical treatment.

Background and Problem Solved

The original patent disclosed pharmaceutical compositions comprising an antibody, glycine, acetate buffer, and polysorbate 80. However, these compositions were not designed for specific, challenging environments. The present inventive concept addresses this limitation by adapting the original compositions for specialized uses, ensuring the pharmaceuticals remain effective and stable in diverse operational settings.

Detailed Description of the Inventive Concept

The inventive concept comprises pharmaceutical compositions according to claim 1, which are specifically designed for disaster relief, high-security storage, high-altitude use, remote medical treatment, and preserving pharmaceuticals in extreme temperatures. For example, a system for disaster relief includes a portable pharmaceutical composition container designed for extreme weather conditions. A method for high-security storage involves storing the pharmaceutical composition in a secure, climate-controlled environment. The pharmaceutical composition for high-altitude use is adapted for use at elevations above 10,000 feet. The system for remote medical treatment includes a pharmaceutical composition designed for use in remote, hard-to-reach areas. The method for preserving pharmaceutical compositions in extreme temperatures involves storing the composition in a thermally-insulated container.

Novelty and Inventive Step

The inventive concept's novelty lies in its adaptation of the original pharmaceutical compositions for specific, narrow markets or unique operational environments. The inventive step is the recognition of the need for specialized pharmaceutical compositions and the development of solutions that address these needs, ensuring the pharmaceuticals remain effective and stable in diverse operational settings.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include additional components or modifications to the pharmaceutical compositions, such as specialized packaging, temperature-control systems, or communication devices for remote monitoring. Variations may also include adapting the compositions for use in other challenging environments, such as space exploration or underwater operations.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including disaster relief, pharmaceutical manufacturing, healthcare, and biotechnology. The target markets include government agencies, NGOs, pharmaceutical companies, and medical organizations operating in challenging environments.

CPC Classifications

SectionClassGroup
A A61 A61K39/39591
A A61 A61K47/12
A A61 A61K47/183
A A61 A61K47/26
C C07 C07K16/244
C C07 C07K2317/76

Field of Art

Pharmaceutical biotechnology, specifically antibody formulation and composition design, involving protein stabilization, buffer systems, and specialized delivery environments

Person of Ordinary Skill (PHOSITA) Profile

A pharmaceutical scientist with advanced degree (PhD/MS) in biotechnology or pharmaceutical sciences, expertise in protein chemistry, formulation development, and understanding of antibody stability factors such as buffer composition, concentration ranges, and environmental interactions

Obviousness Rationale

A PHOSITA would recognize that adapting pharmaceutical compositions for specialized environments represents a predictable engineering variation of known antibody formulation principles. The core compositional elements remain consistent with the source patent, while the novel application demonstrates routine optimization for specific use cases. The disclosed variations represent standard design adaptations within pharmaceutical development that would be obvious to a skilled practitioner seeking to extend pharmaceutical utility.

Obvious Combinations & Variations

Source Patent Element
Antibody composition with specific concentration ranges (120-180 mg/ml) and buffer components (glycine, acetate)
PTD Variation
Adapting the composition for disaster relief and extreme temperature storage environments
Obviousness Reasoning
Predictable extension of formulation stability principles, involving known thermal protection techniques and standard pharmaceutical engineering practices
Source Patent Element
Antibody with IL-17A/IL-17F binding characteristics
PTD Variation
Specialized delivery systems for high-altitude and remote medical treatment scenarios
Obviousness Reasoning
Routine application of existing pharmaceutical composition to novel environmental contexts, representing standard design optimization
Source Patent Element
Pharmaceutical composition with polysorbate 80 and specific buffer concentrations
PTD Variation
High-security storage methods with climate-controlled environmental specifications
Obviousness Reasoning
Obvious implementation of known stabilization techniques using standard pharmaceutical engineering approaches
Source Patent Element
Antibody formulation with defined chemical composition
PTD Variation
Packaging and containment systems designed for extreme operational environments
Obviousness Reasoning
Predictable solution set involving known protective strategies for pharmaceutical preservation
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. ยง 103, the variations disclosed herein would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable extensions of the pharmaceutical composition teachings of US Patent 11857625, involving routine optimization of known formulation principles for specialized environmental applications.

Original Patent Information

Patent NumberUS 11,857,625
TitlePharmaceutical compositions
Assignee(s)UCB BIOPHARMA SRL